NPPA Anti-Cancer Drug Price Revision Overview

Revised maximum retail prices (MRPs) for 1,364 anti-cancer formulations came into effect on November 9, 2026, following price-control interventions implemented by the National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals. Expected to yield annual consumer savings of approximately ₹3,540.38 crore ($372.48 million), the measure stems from trade margin rationalizations imposed across 137 anti-cancer drugs based on recommendations from a Directorate General of Health Services (DGHS) Expert Committee constituted on October 17, 2026. According to the Ministry of Chemicals and Fertilizers, 85 pharmaceutical manufacturers had officially submitted revised MRPs covering 1,364 formulations across 121 molecules as of November 8, 2026. The regulatory price revisions have slashed costs by more than 50% across 679 brands, with the steepest individual price reduction reaching 96.45%. Under the directive, retail chemists and hospital pharmacies are strictly prohibited from charging above the notified MRPs, which patients can verify via updated packaging labels, the Pharma Sahi Daam mobile application, or the official NPPA portal. To enforce compliance and curb overcharging, grievances can be lodged through the Pharma Jan Samadhan platform or the toll-free NPPA helpline (1800-111-255)—a move designed to significantly improve cancer care affordability and ease out-of-pocket financial strain on patients and their families. SUNPHARMA